12/20
02:30 pm
regn
Intellia Crashes 60% in a Year: How Should You Play the Stock? [Yahoo! Finance]
Low
Report
Intellia Crashes 60% in a Year: How Should You Play the Stock? [Yahoo! Finance]
12/19
07:13 am
regn
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results [Yahoo! Finance]
Low
Report
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results [Yahoo! Finance]
12/19
07:00 am
regn
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
Low
Report
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
12/18
11:52 am
regn
REGN's EYLEA HD Improves Vision in RVO Patients [Yahoo! Finance]
Medium
Report
REGN's EYLEA HD Improves Vision in RVO Patients [Yahoo! Finance]
12/18
06:24 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was downgraded by analysts at Canaccord Genuity Group Inc. from a "strong-buy" rating to a "hold" rating.
Medium
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was downgraded by analysts at Canaccord Genuity Group Inc. from a "strong-buy" rating to a "hold" rating.
12/17
04:19 pm
regn
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/17
04:05 pm
regn
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
12/17
08:15 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "hold" rating and a $165.00 price target on the stock.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "hold" rating and a $165.00 price target on the stock.
12/17
07:32 am
regn
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion [Yahoo! Finance]
Low
Report
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion [Yahoo! Finance]
12/17
07:00 am
regn
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
Low
Report
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
12/16
04:39 pm
regn
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year [Yahoo! Finance]
Low
Report
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year [Yahoo! Finance]
12/16
04:30 pm
regn
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
Low
Report
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
12/16
03:22 pm
regn
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases [Yahoo! Finance]
Low
Report
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases [Yahoo! Finance]
12/10
08:20 am
regn
Koneksa Publishes Syndication Model to Accelerate Drug Discovery Using Digital Health Data in Clinical and Translational Science [Yahoo! Finance]
Low
Report
Koneksa Publishes Syndication Model to Accelerate Drug Discovery Using Digital Health Data in Clinical and Translational Science [Yahoo! Finance]
12/10
08:00 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "underperform" rating re-affirmed by analysts at Bank of America Co.. They now have a $565.00 price target on the stock.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "underperform" rating re-affirmed by analysts at Bank of America Co.. They now have a $565.00 price target on the stock.
12/10
07:25 am
regn
Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
Low
Report
Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
12/9
07:35 pm
regn
Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]
Low
Report
Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]
12/9
05:50 pm
regn
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma [Yahoo! Finance]
Low
Report
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma [Yahoo! Finance]
12/9
05:45 pm
regn
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
Low
Report
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
12/9
07:25 am
regn
Regeneron Pharmaceuticals, Inc. Being Investigated on Behalf of Regeneron Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.
Low
Report
Regeneron Pharmaceuticals, Inc. Being Investigated on Behalf of Regeneron Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.
12/7
07:05 pm
regn
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab [Yahoo! Finance]
Low
Report
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab [Yahoo! Finance]
12/7
07:00 pm
regn
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
Low
Report
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
12/6
12:30 pm
regn
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Low
Report
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
12/6
12:00 pm
regn
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
Low
Report
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
12/6
07:25 am
regn
Levi & Korsinsky Reminds Shareholders of an Investigation into Regeneron Pharmaceuticals, Inc. (REGN) Regarding Potential Securities Fraud Allegations
Low
Report
Levi & Korsinsky Reminds Shareholders of an Investigation into Regeneron Pharmaceuticals, Inc. (REGN) Regarding Potential Securities Fraud Allegations